Cancer patients get chance to stay on lifesaving drug in new safety study
NCT ID NCT01742299
Summary
This study allows patients with gastrointestinal stromal tumors (GIST) or chronic myeloid leukemia (CML) who are already benefiting from the drug imatinib to continue receiving it. The main goal is to collect long-term safety information by monitoring patients for side effects. It is open only to people who have already finished a previous Novartis-sponsored study with imatinib and whose doctor believes they should keep taking it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST AND CML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Novartis Investigative Site
Nanjing, Jiangsu, 210002, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Shanghai, 200433, China
-
Novartis Investigative Site
Helsinki, FIN-00029, Finland
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Pessac, 33604, France
-
Novartis Investigative Site
Poitiers, 86021, France
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Cluj-Napoca, Cluj, 400015, Romania
-
Novartis Investigative Site
Bucharest, 022328, Romania
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Basel, 4031, Switzerland
-
Novartis Investigative Site
Bangkok, 10700, Thailand
-
Novartis Investigative Site
Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
-
Novartis Investigative Site
Sutton, Surrey, SM2 5PT, United Kingdom
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
Sidney Kimmel CCC At JH
Baltimore, Maryland, 21231, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University of California LA
Los Angeles, California, 90095, United States
-
Weill Cornell Medical Center
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.